Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt

NCT ID: NCT02138708

Last Updated: 2021-03-26

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-01-31
• Study Completion Date: 2016-03-31

Brief Summary

The purpose of this study is to assess the predictive performance of the pulmonary vascular reactivity to acetylcholine, in the presence pulmonary arterial hypertension (estimated 1 year after the closure of the shunt).

Detailed Description

Pulmonary arterial hypertension (PAH) is an important cause of mortality and morbidity in patients with congenital heart disease with a shunt.

These congenital cardiac shunts are responsible for PAH, which evolves towards higher pulmonary vascular resistance if they are not closed early.

Patients with significant pulmonary flow and low pulmonary vascular resistance fully benefit from surgical shunt closure with complete disappearance of pulmonary hypertension after closure. In contrast, patients with low pulmonary flow and high pulmonary vascular resistance will have no benefit because they keep a deleterious pulmonary hypertension after closure of the shunt.

In certain situations, especially late discovery of heart disease, the issue of operability of these patients is crucial because closing the shunt inappropriately worsens the spontaneous prognosis. Currently, in case of doubt on the operability, there are several clinical and hemodynamic criteria used empirically, but their predictive value is uncertain.

It is therefore necessary to stratify patients into operable and inoperable groups to improve their overall outcome after surgery.

In this research project we propose to assess the predictive performance of the pulmonary vascular reactivity to acetylcholine test on the presence of elevated PAH 1 year after the closure of the shunt. This reactivity test will be evaluated on a population of patients for whom the decision of the surgical closure of the shunt has been adjudicated on the basis of explorations and usual tests (and therefore blind to the knowledge of the result of the reactivity test). The test in this study is designed with repeated injections and increasing doses with a continuous flow of acetylcholine in the left lower lobe of the pulmonary artery. The last injection consisted with adenosine with inhaled O2/NO (potentiating effect) for maximum vasodilatation. The parameter of interest is the Doppler flow velocity in the pulmonary artery endothelium-dependent vasodilation by acetylcholine relative to the speed at maximum vasodilatation (adenosine + in nitric oxide (NO) inhalation)

Conditions

Pulmonary Arterial Hypertension With Congenital Cardiac Shunt

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Shunt closed

patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt

Group Type: EXPERIMENTAL

Pharmacological test of pulmonary endothelial

Intervention Type: OTHER

Interventions

Pharmacological test of pulmonary endothelial

Intervention Type: OTHER

Other Intervention Names

Before any shunt closure operation, the patients will have a the endothelium-dependant reactivity test.; This includes for the same patient : - Implementation of Doppler probe in the lower left lobe guided in one probe 5 catheter guide right coronary 5 Fr; - then control infusion G5%; - then, 3 successive acetylcholine infusions to locally obtain successive concentrations of 10-10, 10-8, 10-6 mol /L; - and infusion of adenosine 50μg/Kg/min with NO inhald/FiO2 100%

Eligibility Criteria

Inclusion Criteria

• Patient child or adult, (regardless of age and weight) , which presents with heart disease with a shunt,
• Patient who requires, during current care, a hemodynamic exploration by catheterization to assess pulmonary vascular resistance (due to doubt on the operability of the patient on the usual clinical and echo cardiographic data) .
• Informed consent signed by the patient or at least one holder of parental authority, and the investigator
• Patient affiliated or benefiting from a social security scheme

Exclusion Criteria

• Patient with a specific treatment for PAH (the prostacyclin derivatives, antagonists of endothelium receptors and inhibitors of phosphodiesterase 5).
• Patient participating in another research with exclusion period
• Known allergy to acetylcholine or adenosine
• Contraindication to the use of KRENOSIN (adenosine)
• atrioventricular block second or third degree, with the exception of patients with cardiac pacemaker.
• dysfunction sinoatrial (the headset disease) except patients with a pacemaker
• chronic obstructive pulmonary disease with bronchospasm (eg bronchial asthma)
• long QT Syndrome
• severe arterial hypotension
• known adenosine hypersensitivity
• Pregnant or patient of childbearing potential not using an effective contraception

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

P120910

Identifier Type: -

Identifier Source: org_study_id